Justin Boxford Appointed Global Brand President, Estée Lauder
23.9.2022 16:00:00 EEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Justin Boxford has been appointed Global Brand President, Estée Lauder, effective September 1, 2022. Justin succeeds Stéphane de La Faverie, whose promotion to Executive Group President was part of an organizational evolution announced last week. In his new role, Justin is reporting to Stéphane and will continue to serve on the company’s Executive Leadership Team (ELT).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005308/en/
Justin Boxford appointed Global Brand President, Estée Lauder; photo courtesy of Kevin Trageser.
As Global Brand President, Justin will be responsible for driving Estée Lauder’s short- and long-term strategy, including innovation, product development, North America and international growth, consumer marketing and distribution evolution. He will partner closely with members of the global Estée Lauder leadership team to drive the brand’s success for the company and build upon its enduring relevance with consumers worldwide.
“Justin is a dynamic leader who brings to Estée Lauder proven prestige and luxury brand-building expertise, a deep understanding of the global business landscape and extensive background in transforming the online and omnichannel experience,” said Stéphane. “His successful track record of leading teams and growing brand aspiration make him the perfect leader to continue building on the outstanding growth and strength of our flagship brand.”
Justin joins Estée Lauder after almost six years at the helm of La Mer, where he drove outstanding results, boosting net sales to become a top-performing brand for the company, as well as solidifying its leadership in global luxury skin care. Under Justin’s leadership, La Mer has expanded and diversified its product portfolio, building multiple hero engines of growth, and successfully launching products that have strengthened the brand’s luxury architecture, from the new serum-strength The Treatment Lotion to the ultra-luxury Genaissance de la Mer™ regimen. Justin has also led the La Mer team to significantly advance claims, credentialing, and science positioning with breakthrough commercial innovation such as the recent pre-/post-derm campaign for The Concentrate.
Justin led the strategic expansion of La Mer across omnichannel platforms to reach new consumers via highly curated, luxury experiences enabled by digital. La Mer has elevated luxury experience standards on key platforms such as Tmall, and on new platforms in emerging markets.
At the heart of his tenure at La Mer, Justin is also credited with amplifying La Mer’s brand purpose through continued dedication to ocean conservation, illustrated by his implementation of sustainable initiatives into the brand’s business model, and a focus on driving awareness with purpose-led storytelling. Justin is recognized for championing La Mer’s purpose across every part of the business by fostering a culture of equity and inclusion internally, and by delivering value and meaning into the hearts of loyal La Mer consumers.
Since joining the company in 2004, Justin has held several leadership roles around the world and across multiple brands, regions, and channels. Prior to joining La Mer, Justin held the position of Senior Vice President, International, Estée Lauder and TOM FORD BEAUTY, and prior to then, Justin lived in Hong Kong where he led the same brands for the Asia-Pacific (APAC) region. Justin was instrumental in advancing the Estée Lauder brand’s digital, omnichannel, and local relevance strategies internationally, helping to achieve its position as the top skin care brand in the world. He also led the successful launch of TOM FORD BEAUTY internationally, including in China and APAC. Previously, Justin was Vice President, Estée Lauder, Travel Retail.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, LAB Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005308/en/
Contact information
Investor Relations:
Rainey Mancini
rmancini@estee.com
Media Relations:
Jill Marvin
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release
The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
